Abstract:Cancer is a perilous life-threatening disease, and attempts are constantly made to create multinuclear transition metal complexes that could lead to potential anticancer medications and administration procedures. Hence, this work aims to design, synthesize, characterize, and assess the anticancer efficacy of ruthenium p-cymene complexes incorporating N, N'- bis(4-substituted benzoyl)hydrazine ligands. The formation of the new complexes (Ru2H1-Ru2H3) has been thoroughly established by elemental analysis, FT-IR, UV-vis, NMR, and HR-MS spectral techniques. The solid-state molecular structures of the complexes Ru2H1 and Ru2H3 have been determined using the SC-XRD study, which confirms the N, O, and Cl-legged piano stool pseudo-octahedral geometry on each ruthenium(II) ion. The stability of these complexes in the solution state and their lipophilicity profile have been determined. Further, the titled complexes were tested for their in vitro anticancer activity against the cancerous H460 (lung cancer cells), SkBr3 (breast cancer cells), HepG2 (liver cancer cells), and Hela (cervical cancer cells) along with non-cancerous (HEK-293) cells. The IC50 results revealed that complex Ru2H3 exhibits potent activity against the proliferation of all four cancer cells and outscored the effect of standard metallodrug cisplatin. This may be attributed to the presence of a couple of lipophilic electron-donating methoxy groups in the ligand scaffold and also the ruthenium(II) p-cymene motifs. Advantageously, all the complexes (Ru2H1-Ru2H3) displayed cytotoxic specificity only towards the cancerous cell by leaving the off-target non-cancerous cells undamaged. Acridine orange/ethidium bromide (AO/EB) staining, Hoechst 33342, Mitochondrial Membrane Potential (MMP), and Reactive Oxygen Species (ROS) staining assays were used to investigate the apoptotic pathway and ROS levels in mitochondria. The results of Western blot analysis confirmed that complexes triggered apoptosis through intrinsic mitochondrial pathway by upregulating Bax and downregulating Bcl-2 proteins. Finally, the extent of apoptosis triggered by complex (Ru2H3) was quantified with the aid of flow cytometry using the Annexin V-FITC/propidium iodide (PI) double-staining technique.

2-Aryl-1 H -imidazo[4,5- f ][1,10]phenanthroline-Based Binuclear Ru(II)/Ir(III)/Re(I) Complexes as Mitochondria Targeting Cancer Stem Cell Therapeutic Agents

Re (I) [2-Aryl-1H-imidazo[4,5-f][1,10]phenanthroline] tricarbonyl chloride complexes for selective cancer therapy via potential DNA damage mechanism‡

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Organometallic Ru(II), Rh(III) and Re(I) complexes of sterane-based bidentate ligands: Synthesis, solution speciation, interaction with biomolecules and anticancer activity

Novel heterobimetallic Ir(III)-Re(I) complexes: design, synthesis and antitumor mechanism investigation

Photostimulated Anticancer Activity of Mitochondria Localized Rhenium(I) Tricarbonyl Complexes Bearing 1H‐imidazo[4,5‐f][1,10]phenanthroline Ligands Against MDA‐MB‐231 Cancer Cells

Exploring the Cytotoxicity of Dinuclear Ru(II) p-cymene Complexes Appended N,N'-Bis(4-substituted benzoyl)hydrazines: Insights into the Mechanism of Apoptotic Cell Death

Neutral Rhenium(I) Tricarbonyl Complexes with Sulfur-Donor Ligands: Anti-Proliferative Activity and Cellular Localization

Iminoamido chelated iridium(III) and ruthenium(II) anticancer complexes with mitochondria-targeting ability and potential to overcome cisplatin resistance

Novel Re(I) Complexes as Potential Selective Theranostic Agents in Cancer Cells and In Vivo in Caenorhabditis elegans Tumoral Strains

Simultaneously Inducing and Tracking Cancer Cell Metabolism Repression by Mitochondria-Immobilized Rhenium(I) Complex

Ru(II)‐Nitrophenylhydrazine/Chlorophenylhydrazine Complexes: Nanoarchitectonics, Biological Evaluation and In silico Study

Photocytotoxic Kinetically Stable Ruthenium(II)-N,N-donor Polypyridyl Complexes of Oxalate for Anticancer Activity Against HepG2 Liver Cancer Cells

Brominated cyclometalated iridium(III) complexes for mitochondrial immobilization as potentiated anticancer agents

Exploring the potential of ruthenium(ii)–phosphine–mercapto complexes as new anticancer agents

Heteronuclear Ru(II)-Re(I) complexes as potential photodynamic anticancer agents with anti-metastatic and anti-angiogenic activities

Aminoquinoline-based Re(I) tricarbonyl complexes: Insights into their antiproliferative activity and mechanisms of action

Half-Sandwich Iridium(III), Rhodium(III), and Ruthenium(II) Complexes Chelating Hybrid sp 2 -N/sp 3 -N Donor Ligands to Achieve Improved Anticancer Selectivity

Anticancer Activities of Re(I) Tricarbonyl and Its Imidazole-Based Ligands: Insight from a Theoretical Approach

Lysosomal Targeted Cyclometallic Iridium(III) Salicylaldehyde-Coumarin Schiff Base Complexes and Anticancer Application

Dinuclear Rhenium(I) Tricarbonyl Complexes as Anticancer Drug Candidates